Investigational drug · Phase 3
APG-2575
Also called: lisaftoclax
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
10
10 still active
All registered trials
27
Any phase or sponsor naming "APG-2575"
First trial start
2020
Aug 31, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "APG-2575", any sponsor or status.
Conditions studied
As listed on its trial records.
- CLL/SLL
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Higher-risk Myelodysplastic Syndrome
- T-Prolymphocytic Leukemia
- Non-Hodgkins Lymphoma
- SLE
- Relapsed/Refractory Acute Myeloid Leukaemia
- Myeloid Malignancy
- Neuroblastoma
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "APG-2575" as an intervention, largest first.
Ascentage Pharma Group Inc.Industry
NCT04501120 · 682 participants (planned) · Start Sep 28, 2020 · Primary completion Sep 2028
Drug: Lisaftoclax (APG-2575); Reduced-dose HHT and 4 more · For: Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 12 sites in all
- Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).Pivotal-lookingRecruiting
Ascentage Pharma Group Inc.Industry
NCT06641414 · 490 participants (planned) · Start Jan 22, 2025 · Primary completion Jun 2029
Drug: Lisaftoclax (APG-2575); Azacitidine Injection · For: Higher-risk Myelodysplastic Syndrome
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 155 sites in all
- A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Ascentage Pharma Group Inc.Industry
NCT06389292 · 486 participants (planned) · Start Jun 11, 2024 · Primary completion May 25, 2028
Drug: APG-2575(Lisaftoclax ); Azacitidine Injection · For: Acute Myeloid Leukemia
Sites: Tianjin, China; Hangzhou, China; Moscow, Russia · 6 sites in all
- Global Trial in APG2575 for Patients With CLL/SLLPivotal-lookingRecruiting
Ascentage Pharma Group Inc.Industry
NCT06104566 · 400 participants (planned) · Start Dec 20, 2023 · Primary completion Dec 31, 2026
Drug: lisaftoclax +BTK inhibitor; BTK inhibitor · For: CLL/SLL
Sites: Tuscon, Arizona; Anaheim, California; Jacksonville, Florida · 135 sites in all
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.Pivotal-lookingRecruiting
Ascentage Pharma Group Inc.Industry
NCT06319456 · 344 participants (planned) · Start Apr 7, 2024 · Primary completion Aug 2027
Drug: Lisaftoclax (APG-2575); Acalabrutinib and 4 more · For: CLL/SLL
Sites: Bengbu, China; Guangzhou, China; Zhanjiang, China · 10 sites in all
- Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLLRecruiting
Ascentage Pharma Group Inc.Industry
NCT04215809 · 144 participants (planned) · Start Mar 2, 2020 · Primary completion Oct 31, 2025
Drug: Lisaftoclax · For: CLL/SLL
Sites: Duarte, California; Jacksonville, Florida; Boston, Massachusetts · 9 sites in all
- Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLRecruiting
Ascentage Pharma Group Inc.Industry
NCT04494503 · 123 participants (planned) · Start Aug 31, 2020 · Primary completion Oct 20, 2024
Drug: APG-2575; Rituximab and 1 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 18 sites in all
- APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknown
Ascentage Pharma Group Inc.Industry
NCT04942067 · 108 participants (planned) · Start Dec 23, 2021 · Primary completion Sep 1, 2024
Drug: APG-2575+ Pd; APG-2575 + DRd · For: Multiple Myeloma; Amyloidosis
Sites: Jacksonville, Florida; New York, New York; Cleveland, Ohio
Ascentage Pharma Group Inc.Industry
NCT05701306 · 100 participants (planned) · Start Feb 28, 2023 · Primary completion Jun 1, 2027
Drug: APG-115; APG-2575 · For: Neuroblastoma; Solid Tumor
Sites: Guangzhou, China; Wuhan, China; Tianjin, China
- APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic MalignanciesStatus unknown
Ascentage Pharma Group Inc.Industry
NCT03537482 · 90 participants (planned) · Start Aug 7, 2018 · Primary completion Sep 15, 2024
Drug: APG-2575 · For: Hematologic Malignancies
Sites: Jacksonville, Florida; Durham, North Carolina; Houston, Texas · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Acute myeloid leukemia following icotinib therapy for non-small cell lung cancer: a case report and literature review.
Huang H, Song L, Tong F, et al. · Front Oncol 2026
- DHODH Drives Sunitinib Resistance Via a Non-Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC.
Qian S, Pu S, Xu Z, et al. · Adv Sci (Weinh) 2026
- Case Report: A unique case of Philadelphia chromosome-positive mixed-phenotype acute leukemia with active Epstein-Barr virus infection in a kidney transplantation recipient.
Chen M, Hu X, Feng W, et al. · Front Oncol 2026
- Efficacy and Safety of Azacitidine Combined With Lisaftoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome With Increased Blasts.
Meng S, Zhao W, Zhang H, et al. · EJHaem 2026
- Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas.
Sun M, Zhou K, Qi J, et al. · Clin Lymphoma Myeloma Leuk 2026
- Lisaftoclax combined with ixazomib and dexamethasone after CAR-T for maintenance therapy in transplant-ineligible relapsed/refractory ultra-high-risk multiple myeloma: two case reports and literature review.
Xu W, Qiao X, Zhang L, et al. · Front Oncol 2026
Also in development for CLL/SLL
- CTXPhase 32 trials
Ascentage Pharma Group Inc. · CLL/SLL, Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.